ArticleMolecular biology reports2026
PARP1 genetic variants modulate gene expression and cervical cancer susceptibility in a North Indian case-control study.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPoly (ADP-ribose) polymerase 1 (PARP1) is a nuclear protein involved in the DNA repair pathway. The aim of this investigation was to assess the association of PARP1 polymorphisms with PARP1 expression and cervical cancer susceptibility in North Indian women. METHODS AND
resultsThis was a case-control study comprised of 141 cervical cancer patients and 147 healthy controls. The PCR-RFLP was performed for genotypic distribution. The qRT-PCR and immunohistochemistry were performed to check PARP1 gene and protein expression, respectively. The homozygous CC (rs1136410) in the genotype model was found to be significant (P = 0.002); however, the interval of the odds ratio was wide, thereby leading to an unstable association. In the additive model, the association was significant, but the odds ratio was less than 2, whereas the dominant model was significantly correlated with cervical cancer with a high odds ratio (P = 0.002; OR = 2.34). The heterozygous CT (rs7527192) was associated with cervical cancer in the genotype model (OR = 2.37). The dominant and additive models were also significantly associated with cervical cancer, conferring a 2.71 and 2.36 times higher risk. The gene and protein expression of PARP1 was higher in cervical cancer patients. There was an association of CC genotype (rs1136410) and PARP1 expression as per the Kruskal-Wallis test, but no such association was found in rs7527192 polymorphism.
conclusionsThe findings suggest that rs7527192 may be associated with cervical cancer susceptibility in this cohort, and rs1136410 influences the PARP1 expression; however, independent validation in larger, multiethnic, and functionally characterized cohorts with HPV adjustment is required.
Indexed as
Identifiers
42658306What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.